title: Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors.
abstract: Acting through a number of distinct pathways, many G protein-coupled receptors (GPCRs) activate the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) cascade. Recently, it has been shown that in some cases, clathrin-mediated endocytosis is required for GPCR activation of the ERK/MAPK cascade, whereas in others it is not. Accordingly, we compared ERK activation mediated by a GPCR that does not undergo agonist-stimulated endocytosis, the alpha(2A) adrenergic receptor (alpha(2A) AR), with ERK activation mediated by the beta(2) adrenergic receptor (beta(2) AR), which is endocytosed. Surprisingly, we found that in COS-7 cells, ERK activation by the alpha(2A) AR, like that mediated by both the beta(2) AR and the epidermal growth factor receptor (EGFR), is sensitive to mechanistically distinct inhibitors of clathrin-mediated endocytosis, including monodansylcadaverine, a mutant dynamin I, and a mutant beta-arrestin 1. Moreover, we determined that, as has been shown for many other GPCRs, both alpha(2A) and beta(2) AR-mediated ERK activation involves transactivation of the EGFR. Using confocal immunofluorescence microscopy, we found that stimulation of the beta(2) AR, the alpha(2A) AR, or the EGFR each results in internalization of a green fluorescent protein-tagged EGFR. Although beta(2) AR stimulation leads to redistribution of both the beta(2) AR and EGFR, activation of the alpha(2A) AR leads to redistribution of the EGFR but the alpha(2A) AR remains on the plasma membrane. These findings separate GPCR endocytosis from the requirement for clathrin-mediated endocytosis in EGFR transactivation-mediated ERK activation and suggest that it is the receptor tyrosine kinase or another downstream effector that must engage the endocytic machinery.
authors.affiliation: Howard Hughes Medical Institute, Departments of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: K L
authors.initials: KL
authors.lastname: Pierce
authors.forename: S
authors.initials: S
authors.lastname: Maudsley
authors.forename: Y
authors.initials: Y
authors.lastname: Daaka
authors.forename: L M
authors.initials: LM
authors.lastname: Luttrell
authors.forename: R J
authors.initials: RJ
authors.lastname: Lefkowitz
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D000068438:Brimonidine Tartrate; D019556:COS Cells; D002966:Clathrin / Q000378:metabolism; D004705:Endocytosis; D004791:Enzyme Inhibitors; D004815:Epidermal Growth Factor / Q000494:pharmacology; D066246:ErbB Receptors / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D019204:GTP-Binding Proteins / Q000378:metabolism*; D007545:Isoproterenol / Q000494:pharmacology; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D010766:Phosphorylation; D011799:Quinazolines; D011810:Quinoxalines / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000378:metabolism*; D014162:Transfection; D020032:Tyrphostins / Q000494:pharmacology
chemical_list: D000316:Adrenergic alpha-Agonists; D002966:Clathrin; D004791:Enzyme Inhibitors; D011799:Quinazolines; D011810:Quinoxalines; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D011956:Receptors, Cell Surface; D020032:Tyrphostins; C101044:RTKI cpd; D000068438:Brimonidine Tartrate; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D020928:Mitogen-Activated Protein Kinases; D019204:GTP-Binding Proteins; D007545:Isoproterenol